Background: Interactions between HIV and opioid-dependence therapies are known to occur. We sought to determine if such interactions occurred between buprenorphine/naloxone and elvitegravir boosted with cobicistat.
Methods: We performed a within-subject open-labeled pharmacokinetic and pharmacodynamic study in 17 HIV-seronegative subjects stabilized on at least 2 weeks of buprenorphine/naloxone therapy. Subjects underwent baseline and steady state evaluation of the effect of elvitegravir 150 mg once daily boosted with 150 mg once daily of cobicistat (EVG/COBI) on buprenorphine/naloxone parameters. Safety was monitored throughout the study.
Results: Compared with baseline values, buprenorphine mean AUCtau (69.0 versus 95.6 hr*ng/mL) and mean Cmax (8.4 versus 9.3 ng/mL) increased significantly in the presence of EVG/COBI. Compared with baseline values, norbuprenorphine mean AUCtau (103.4 versus 163.4 hr*ng/mL) and mean Cmax (6.9 versus 9 ng/mL) also increased significantly after achieving steady state EVG/COBI. Naloxone mean AUCtau (0.57 versus 0.45 hr*ng/mL) and mean Cmax (0.25 versus 0.16 ng/mL) decreased after the addition of EVG/COBI. The AUCtau, Cmax and Ctau of EVG and cobicistat did not significantly differ from historical controls. Opioid withdrawal or overdose was not observed among subjects in this study.
Conclusion: The addition of EVG/COBI to stabilized patients receiving buprenorphine/naloxone modestly increased buprenorphine and norbuprenorphine levels without affecting the opioid pharmacodynamics.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/QAI.0b013e3182961d31 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Bupropion Increased More than Five Times the Systemic Exposure to Aripiprazole: An In Vivo Study in Rats.
Metabolites
October 2024
Department of Pharmaceutical Technology and Biopharmacy, Faculty of Pharmacy, "Iuliu Hațieganu" University of Medicine and Pharmacy, 41 Victor Babeș Street, 400012 Cluj-Napoca, Romania.
: In psychiatric disorders, antipsychotics and antidepressant medication are often administered together. Aripiprazole, a third-generation antipsychotic drug, is extensively metabolized by CYP2D6 and CYP3A4 isoenzymes, while bupropion, used in depressive disorders, is known as a moderate or strong CYP2D6 enzyme inhibitor. This in vivo experiment aimed to assess the presence of a pharmacokinetic drug interaction between aripiprazole and bupropion and its magnitude on the systemic exposure of aripiprazole.
View Article and Find Full Text PDFPharmacokinetics and tolerability of the dual TORC1/2 inhibitor sapanisertib in combination with the MEK inhibitor trametinib in dogs.
Front Vet Sci
December 2022
Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States.
Activation of one or both the Ras/MAPK and PI3K/Akt/mTOR signal transduction pathways are known to mediate oncogenicity of several canine and human cancers, including mucosal melanomas. Reciprocal cross activation between the two pathways can be a source of drug resistance. Consequently, oral dosing for plasma pharmacokinetic (PK) analysis and tolerability to a combination of sapanisertib, a dual TORC1/2 inhibitor, and trametinib, a MEK inhibitor, was evaluated in nontumor-bearing laboratory dogs for its potential application in parallel pathway targeting.
View Article and Find Full Text PDFScaffold hopping via ring opening enables identification of acyclic compounds as new complement Factor D inhibitors.
Bioorg Med Chem
November 2022
Department of Discovery Chemistry, BioCryst Pharmaceuticals Inc, Discovery Center of Excellence, 2100 Riverchase Center Building 200, Suite 200, Birmingham, AL 35244, United States; Department of Discovery Bioanalytical Chemistry, BioCryst Pharmaceuticals Inc, Discovery Center of Excellence, 2100 Riverchase Center Building 200, Suite 200, Birmingham, AL 35244, United States; Department of Computational Chemistry and Structural Biology, BioCryst Pharmaceuticals Inc, Discovery Center of Excellence, 2100 Riverchase Center Building 200, Suite 200, Birmingham, AL 35244, United States. Electronic address:
The three complement pathways comprising the early phase of the complement system (the classical, lectin, and alternative pathways) act together with the innate and adaptive immune systems to protect against foreign entities and maintain tissue homeostasis. While these systems are normally under tight regulatory control, several diseases have been reported to correlate with uncontrolled activation and amplification of the alternative pathway, including paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, C3 glomerulopathy, and age-related macular degeneration. Complement FactorD (CFD), a serine protease, is the rate-limiting enzyme for the activity of alternative pathway.
View Article and Find Full Text PDFPharmacokinetics of extended-release ivermectin microspheres after oral administration to healthy pigs.
J Vet Pharmacol Ther
September 2020
College of Veterinary Medicine, South China Agricultural University, Guangzhou, China.
We compared the pharmacokinetics of ivermectin premix and ivermectin microspheres in pigs after single and multiple administration regimes. In the single-dose experiments, 24 piglets were randomly divided into three groups and given ivermectin at 0.3 mg/kg using (a) 1.
View Article and Find Full Text PDFComparison of Pharmacokinetics of Aprepitant in Healthy Chinese and Caucasian Subjects.
Drug Des Devel Ther
February 2021
Department of Clinical Pharmacology, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.
Article Synopsis
- Aprepitant (EMEND) is a drug used to prevent nausea and vomiting from chemotherapy, and a study assessed its safety and pharmacokinetics (how the drug moves in the body) in healthy Chinese and Caucasian individuals.
- The study involved 24 subjects (12 from each ethnicity) who received a single dose of aprepitant, and after a washout period, only Chinese subjects took it again for three days, with blood samples collected for analysis.
- Results showed no serious side effects in either group, with similar drug absorption and concentration levels between the ethnicities, confirming that aprepitant is safe and well-tolerated for both groups.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!